AI Based Discovery of a New AKR1C3 Inhibitor for Anticancer Applications
Research output: Contribution to journal › Letter › Research › peer-review
Standard
AI Based Discovery of a New AKR1C3 Inhibitor for Anticancer Applications. / Pippione, Agnese C.; Vigato, Chiara; Tucciarello, Cristina; Hussain, Samrina; Salladini, Edoardo; Truong, Ha H.; Henriksen, Niel M.; Vanzetti, Gaia; Giordano, Giorgia; Zonari, Daniele; Mirza, Osman Asghar; Frydenvang, Karla; Pignochino, Ymera; Oliaro-Bosso, Simonetta; Boschi, Donatella; Lolli, Marco L.
In: ACS Medicinal Chemistry Letters, 2024.Research output: Contribution to journal › Letter › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - AI Based Discovery of a New AKR1C3 Inhibitor for Anticancer Applications
AU - Pippione, Agnese C.
AU - Vigato, Chiara
AU - Tucciarello, Cristina
AU - Hussain, Samrina
AU - Salladini, Edoardo
AU - Truong, Ha H.
AU - Henriksen, Niel M.
AU - Vanzetti, Gaia
AU - Giordano, Giorgia
AU - Zonari, Daniele
AU - Mirza, Osman Asghar
AU - Frydenvang, Karla
AU - Pignochino, Ymera
AU - Oliaro-Bosso, Simonetta
AU - Boschi, Donatella
AU - Lolli, Marco L.
N1 - Publisher Copyright: © 2024 American Chemical Society
PY - 2024
Y1 - 2024
N2 - AKR1C3 is an upregulated enzyme in prostate and other cancers; in addition to regulating hormone synthesis, this enzyme is thought to play a role in the aggressiveness of tumors and in the defense against drugs. We here used an unbiased method to discover new potent AKR1C3 inhibitors: through an AI-based virtual drug screen, compound 4 was identified as a potent and selective enzymatic inhibitor able to translate this activity into a pronounced antiproliferative effect in the 22RV1 prostate cancer cell model. As other known AKR1C3 inhibitors, compound 4 determined a significantly increased activity of abiraterone, a drug approved for advanced prostate cancer. Compound 4 also showed a synergic effect with doxorubicin in osteosarcoma cell lines; specifically, the effect is correlated with AKR1C3 expression. In this research work, therefore, the use of AI allowed the identification of a new structure as an AKR1C3 inhibitor and its potential to enhance the effect of chemotherapeutics.
AB - AKR1C3 is an upregulated enzyme in prostate and other cancers; in addition to regulating hormone synthesis, this enzyme is thought to play a role in the aggressiveness of tumors and in the defense against drugs. We here used an unbiased method to discover new potent AKR1C3 inhibitors: through an AI-based virtual drug screen, compound 4 was identified as a potent and selective enzymatic inhibitor able to translate this activity into a pronounced antiproliferative effect in the 22RV1 prostate cancer cell model. As other known AKR1C3 inhibitors, compound 4 determined a significantly increased activity of abiraterone, a drug approved for advanced prostate cancer. Compound 4 also showed a synergic effect with doxorubicin in osteosarcoma cell lines; specifically, the effect is correlated with AKR1C3 expression. In this research work, therefore, the use of AI allowed the identification of a new structure as an AKR1C3 inhibitor and its potential to enhance the effect of chemotherapeutics.
KW - AI drug design
KW - AKR1C3 inhibitors
KW - doxorubicin.
KW - Osteosarcoma
KW - Prostate Cancer
U2 - 10.1021/acsmedchemlett.4c00150
DO - 10.1021/acsmedchemlett.4c00150
M3 - Letter
AN - SCOPUS:85197561581
JO - ACS Medicinal Chemistry Letters
JF - ACS Medicinal Chemistry Letters
SN - 1948-5875
ER -
ID: 398427450